Global Influenza Vaccination Industry Research Report, Growth Trends and Competitive Analysis 2022-2028

Influenza (flu) is a contagious respiratory disease caused by influenza viruses that infect the respiratory tract (nose, throat, and lungs) in humans. The symptoms and complications of flu are more severe than common cold. The symptoms associated with influenza may include fever, headache, malaise, cough, sore throat, nasal congestion, and body aches. Influenza vaccine can prevent illness and death caused

Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Influenza Vaccination estimated at US$ 3682.5 million in the year 2022, is projected to reach a revised size of US$ 4872.9 million by 2028, growing at a CAGR of 4.8% during the forecast period 2022-2028.

Stringent regulatory framework along with the low accessibility of the product in the developing countries may restrain the market growth.

Report Scope

This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Influenza Vaccination companies, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

This report also includes a discussion of the major players across each regional Influenza Vaccination market. Further, it explains the major drivers and regional dynamics of the global Influenza Vaccination market and current trends within the industry.

Key Companies Covered

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

Abbott (U.S.)

AstraZeneca (Europe)

BioCryst Pharmaceuticals (U.S.)

Novartis (Europe)

DAIICHI SANKYO COMPANY (Asia Pacific)

GlaxoSmithKline (Europe)

Hualan Biological Engineering (Asia Pacific)

Mitsubishi Tanabe Pharma (Asia Pacific)

F. Hoffmann-La Roche (Europe)

Sanofi (Europe)

Market Segments

This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.

Egg Based

Cell Culture

Recombinant

Hospitals

Research Organizations

Key Regions & Countries

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Influenza Vaccination market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Report Includes:

This report presents an overview of global market for Influenza Vaccination market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.

This report researches the key producers of Influenza Vaccination, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Influenza Vaccination, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Influenza Vaccination revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Influenza Vaccination market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Influenza Vaccination revenue, projected growth trends, production technology, application and end-user industry.

Descriptive company profiles of the major global players, including Abbott (U.S.), AstraZeneca (Europe), BioCryst Pharmaceuticals (U.S.), Novartis (Europe), DAIICHI SANKYO COMPANY (Asia Pacific), GlaxoSmithKline (Europe), Hualan Biological Engineering (Asia Pacific), Mitsubishi Tanabe Pharma (Asia Pacific) and F. Hoffmann-La Roche (Europe), etc.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Influenza Vaccination Market Size Growth Rate by Type: 2017 VS 2021 VS 2028

1.2.2 Egg Based

1.2.3 Cell Culture

1.2.4 Recombinant

1.3 Market by Application

1.3.1 Global Influenza Vaccination Market Growth Rate by Application: 2017 VS 2021 VS 2028

1.3.2 Hospitals

1.3.3 Research Organizations

1.4 Study Objectives

1.5 Years Considered

2.1 Global Influenza Vaccination Market Size (2017-2028)

2.2 Influenza Vaccination Market Size across Key Geographies Worldwide: 2017 VS 2021 VS 2028

2.3 Global Influenza Vaccination Market Size by Region (2017-2022)

2.4 Global Influenza Vaccination Market Size Forecast by Region (2023-2028)

2.5 Global Top Influenza Vaccination Countries Ranking by Market Size

3.1 Global Influenza Vaccination Revenue by Players

3.1.1 Global Influenza Vaccination Revenue by Players (2017-2022)

3.1.2 Global Influenza Vaccination Market Share by Players (2017-2022)

3.2 Global Influenza Vaccination Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Company Covered: Ranking by Influenza Vaccination Revenue

3.4 Global Influenza Vaccination Market Concentration Ratio

3.4.1 Global Influenza Vaccination Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Influenza Vaccination Revenue in 2021

3.5 Global Influenza Vaccination Key Players Head office and Area Served

3.6 Key Players Influenza Vaccination Product Solution and Service

3.7 Date of Enter into Influenza Vaccination Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Influenza Vaccination Historic Revenue by Type (2017-2022)

4.2 Global Influenza Vaccination Forecasted Revenue by Type (2023-2028)

5.1 Global Influenza Vaccination Historic Market Size by Application (2017-2022)

5.2 Global Influenza Vaccination Forecasted Market Size by Application (2023-2028)

6.1 North America Influenza Vaccination Revenue by Company (2020-2022)

6.2 North America Influenza Vaccination Revenue by Type (2017-2028)

6.3 North America Influenza Vaccination Revenue by Application (2017-2028)

6.4 North America Influenza Vaccination Revenue by Country (2017-2028)

6.4.1 U.S.

6.4.2 Canada

7.1 Europe Influenza Vaccination Revenue by Company (2020-2022)

7.2 Europe Influenza Vaccination Revenue by Type (2017-2028)

7.3 Europe Influenza Vaccination Revenue by Application (2017-2028)

7.4 Europe Influenza Vaccination Revenue by Country (2017-2028)

7.4.1 Germany

7.4.2 France

7.4.3 U.K.

7.4.4 Italy

7.4.5 Russia

8.1 Asia Pacific Influenza Vaccination Revenue by Company (2020-2022)

8.2 Asia Pacific Influenza Vaccination Revenue by Type (2017-2028)

8.3 Asia Pacific Influenza Vaccination Revenue by Application (2017-2028)

8.4 Asia Pacific Influenza Vaccination Revenue by Region (2017-2028)

8.4.1 China

8.4.2 Japan

8.4.3 South Korea

8.4.4 India

8.4.5 Australia

8.4.6 Taiwan

8.4.7 Indonesia

8.4.8 Thailand

8.4.9 Malaysia

8.4.10 Philippines

8.4.11 Vietnam

9.1 Latin America Influenza Vaccination Revenue by Company (2020-2022)

9.2 Latin America Influenza Vaccination Revenue by Type (2017-2028)

9.3 Latin America Influenza Vaccination Revenue by Application (2017-2028)

9.4 Latin America Influenza Vaccination Revenue by Country (2017-2028)

9.4.1 Mexico

9.4.2 Brazil

9.4.3 Argentina

10.1 Middle East and Africa Influenza Vaccination Revenue by Company (2020-2022)

10.2 Middle East and Africa Influenza Vaccination Revenue by Type (2017-2028)

10.3 Middle East and Africa Influenza Vaccination Revenue by Application (2017-2028)

10.4 Middle East and Africa Influenza Vaccination Revenue by Country (2017-2028)

10.4.1 Turkey

10.4.2 Saudi Arabia

10.4.3 U.A.E

11.1 Abbott (U.S.)

11.1.1 Abbott (U.S.) Company Details

11.1.2 Abbott (U.S.) Business Overview

11.1.3 Abbott (U.S.) Influenza Vaccination Products and Services

11.1.4 Abbott (U.S.) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.1.5 Abbott (U.S.) Influenza Vaccination SWOT Analysis

11.1.6 Abbott (U.S.) Recent Developments

11.2 AstraZeneca (Europe)

11.2.1 AstraZeneca (Europe) Company Details

11.2.2 AstraZeneca (Europe) Business Overview

11.2.3 AstraZeneca (Europe) Influenza Vaccination Products and Services

11.2.4 AstraZeneca (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.2.5 AstraZeneca (Europe) Influenza Vaccination SWOT Analysis

11.2.6 AstraZeneca (Europe) Recent Developments

11.3 BioCryst Pharmaceuticals (U.S.)

11.3.1 BioCryst Pharmaceuticals (U.S.) Company Details

11.3.2 BioCryst Pharmaceuticals (U.S.) Business Overview

11.3.3 BioCryst Pharmaceuticals (U.S.) Influenza Vaccination Products and Services

11.3.4 BioCryst Pharmaceuticals (U.S.) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.3.5 BioCryst Pharmaceuticals (U.S.) Influenza Vaccination SWOT Analysis

11.3.6 BioCryst Pharmaceuticals (U.S.) Recent Developments

11.4 Novartis (Europe)

11.4.1 Novartis (Europe) Company Details

11.4.2 Novartis (Europe) Business Overview

11.4.3 Novartis (Europe) Influenza Vaccination Products and Services

11.4.4 Novartis (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.4.5 Novartis (Europe) Influenza Vaccination SWOT Analysis

11.4.6 Novartis (Europe) Recent Developments

11.5 DAIICHI SANKYO COMPANY (Asia Pacific)

11.5.1 DAIICHI SANKYO COMPANY (Asia Pacific) Company Details

11.5.2 DAIICHI SANKYO COMPANY (Asia Pacific) Business Overview

11.5.3 DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination Products and Services

11.5.4 DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.5.5 DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination SWOT Analysis

11.5.6 DAIICHI SANKYO COMPANY (Asia Pacific) Recent Developments

11.6 GlaxoSmithKline (Europe)

11.6.1 GlaxoSmithKline (Europe) Company Details

11.6.2 GlaxoSmithKline (Europe) Business Overview

11.6.3 GlaxoSmithKline (Europe) Influenza Vaccination Products and Services

11.6.4 GlaxoSmithKline (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.6.5 GlaxoSmithKline (Europe) Influenza Vaccination SWOT Analysis

11.6.6 GlaxoSmithKline (Europe) Recent Developments

11.7 Hualan Biological Engineering (Asia Pacific)

11.7.1 Hualan Biological Engineering (Asia Pacific) Company Details

11.7.2 Hualan Biological Engineering (Asia Pacific) Business Overview

11.7.3 Hualan Biological Engineering (Asia Pacific) Influenza Vaccination Products and Services

11.7.4 Hualan Biological Engineering (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.7.5 Hualan Biological Engineering (Asia Pacific) Influenza Vaccination SWOT Analysis

11.7.6 Hualan Biological Engineering (Asia Pacific) Recent Developments

11.8 Mitsubishi Tanabe Pharma (Asia Pacific)

11.8.1 Mitsubishi Tanabe Pharma (Asia Pacific) Company Details

11.8.2 Mitsubishi Tanabe Pharma (Asia Pacific) Business Overview

11.8.3 Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination Products and Services

11.8.4 Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.8.5 Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination SWOT Analysis

11.8.6 Mitsubishi Tanabe Pharma (Asia Pacific) Recent Developments

11.9 F. Hoffmann-La Roche (Europe)

11.9.1 F. Hoffmann-La Roche (Europe) Company Details

11.9.2 F. Hoffmann-La Roche (Europe) Business Overview

11.9.3 F. Hoffmann-La Roche (Europe) Influenza Vaccination Products and Services

11.9.4 F. Hoffmann-La Roche (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.9.5 F. Hoffmann-La Roche (Europe) Influenza Vaccination SWOT Analysis

11.9.6 F. Hoffmann-La Roche (Europe) Recent Developments

11.10 Sanofi (Europe)

11.10.1 Sanofi (Europe) Company Details

11.10.2 Sanofi (Europe) Business Overview

11.10.3 Sanofi (Europe) Influenza Vaccination Products and Services

11.10.4 Sanofi (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022)

11.10.5 Sanofi (Europe) Influenza Vaccination SWOT Analysis

11.10.6 Sanofi (Europe) Recent Developments

12.1 Influenza Vaccination Market Trends

12.2 Influenza Vaccination Market Drivers

12.3 Influenza Vaccination Market Challenges

12.4 Influenza Vaccination Market Restraints

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Author Details

List of Tables

    Table 1. Global Influenza Vaccination Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028

    Table 2. Key Players of Egg Based

    Table 3. Key Players of Cell Culture

    Table 4. Key Players of Recombinant

    Table 5. Global Influenza Vaccination Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028

    Table 6. Global Influenza Vaccination Market Size (US$ Million) by Region: 2017 VS 2021 VS 2028

    Table 7. Global Influenza Vaccination Revenue by Region (2017-2022) & (US$ Million)

    Table 8. Global Influenza Vaccination Revenue Market Share by Region (2017-2022)

    Table 9. Global Influenza Vaccination Revenue by Players (2017-2022) & (US$ Million)

    Table 10. Global Influenza Vaccination Market Share by Players (2017-2022)

    Table 11. Global Top Influenza Vaccination Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccination as of 2021)

    Table 12. Ranking of Global Top Influenza Vaccination Companies by Revenue (US$ Million) in 2021

    Table 13. Global 5 Largest Players Market Share by Influenza Vaccination Revenue (CR5 and HHI) & (2017-2022)

    Table 14. Key Players Headquarters and Area Served

    Table 15. Key Players Influenza Vaccination Product Solution and Service

    Table 16. Date of Key Manufacturers Enter into Influenza Vaccination Market

    Table 17. Mergers & Acquisitions, Expansion Plans

    Table 18. Global Influenza Vaccination Market Size by Type (2017-2022) & (US$ Million)

    Table 19. Global Influenza Vaccination Revenue Market Share by Type (2017-2022)

    Table 20. Global Influenza Vaccination Forecasted Market Size by Type (2023-2028) & (US$ Million)

    Table 21. Global Influenza Vaccination Revenue Market Share by Type (2023-2028)

    Table 22. Global Influenza Vaccination Market Size by Application (2017-2022) & (US$ Million)

    Table 23. Global Influenza Vaccination Revenue Market Share by Application (2017-2022)

    Table 24. Global Influenza Vaccination Forecasted Market Size by Application (2023-2028) & (US$ Million)

    Table 25. Global Influenza Vaccination Revenue Market Share by Application (2023-2028)

    Table 26. North America Influenza Vaccination Revenue by Company (2020-2022) & (US$ Million)

    Table 27. North America Influenza Vaccination Revenue by Type (2017-2022) & (US$ Million)

    Table 28. North America Influenza Vaccination Revenue by Type (2023-2028) & (US$ Million)

    Table 29. North America Influenza Vaccination Revenue by Application (2017-2022) & (US$ Million)

    Table 30. North America Influenza Vaccination Revenue by Application (2023-2028) & (US$ Million)

    Table 31. North America Influenza Vaccination Revenue by Country (2017-2022) & (US$ Million)

    Table 32. North America Influenza Vaccination Revenue by Country (2023-2028) & (US$ Million)

    Table 33. Europe Influenza Vaccination Revenue by Company (2020-2022) & (US$ Million)

    Table 34. Europe Influenza Vaccination Revenue by Type (2017-2022) & (US$ Million)

    Table 35. Europe Influenza Vaccination Revenue by Type (2023-2028) & (US$ Million)

    Table 36. Europe Influenza Vaccination Revenue by Application (2017-2022) & (US$ Million)

    Table 37. Europe Influenza Vaccination Revenue by Application (2023-2028) & (US$ Million)

    Table 38. Europe Influenza Vaccination Revenue by Country (2017-2022) & (US$ Million)

    Table 39. Europe Influenza Vaccination Revenue by Country (2023-2028) & (US$ Million)

    Table 40. Asia Pacific Influenza Vaccination Revenue by Company (2020-2022) & (US$ Million)

    Table 41. Asia Pacific Influenza Vaccination Revenue by Type (2017-2022) & (US$ Million)

    Table 42. Asia Pacific Influenza Vaccination Revenue by Type (2023-2028) & (US$ Million)

    Table 43. Asia Pacific Influenza Vaccination Revenue by Application (2017-2022) & (US$ Million)

    Table 44. Asia Pacific Influenza Vaccination Revenue by Application (2023-2028) & (US$ Million)

    Table 45. Asia Pacific Influenza Vaccination Revenue by Region (2017-2022) & (US$ Million)

    Table 46. Asia Pacific Influenza Vaccination Revenue by Region (2023-2028) & (US$ Million)

    Table 47. Latin America Influenza Vaccination Revenue by Company (2020-2022) & (US$ Million)

    Table 48. Latin America Influenza Vaccination Revenue by Type (2017-2022) & (US$ Million)

    Table 49. Latin America Influenza Vaccination Revenue by Type (2023-2028) & (US$ Million)

    Table 50. Latin America Influenza Vaccination Revenue by Application (2017-2022) & (US$ Million)

    Table 51. Latin America Influenza Vaccination Revenue by Application (2023-2028) & (US$ Million)

    Table 52. Latin America Influenza Vaccination Revenue by Country (2017-2022) & (US$ Million)

    Table 53. Latin America Influenza Vaccination Revenue by Country (2023-2028) & (US$ Million)

    Table 54. Middle East and Africa Influenza Vaccination Revenue by Company (2020-2022) & (US$ Million)

    Table 55. Middle East and Africa Influenza Vaccination Revenue by Type (2017-2022) & (US$ Million)

    Table 56. Middle East and Africa Influenza Vaccination Revenue by Type (2023-2028) & (US$ Million)

    Table 57. Middle East and Africa Influenza Vaccination Revenue by Application (2017-2022) & (US$ Million)

    Table 58. Middle East and Africa Influenza Vaccination Revenue by Application (2023-2028) & (US$ Million)

    Table 59. Middle East and Africa Influenza Vaccination Revenue by Country (2017-2022) & (US$ Million)

    Table 60. Middle East and Africa Influenza Vaccination Revenue by Country (2023-2028) & (US$ Million)

    Table 61. Abbott (U.S.) Company Details

    Table 62. Abbott (U.S.) Business Overview

    Table 63. Abbott (U.S.) Influenza Vaccination Product and Services

    Table 64. Abbott (U.S.) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 65. Abbott (U.S.) Influenza Vaccination SWOT Analysis

    Table 66. Abbott (U.S.) Recent Developments

    Table 67. AstraZeneca (Europe) Company Details

    Table 68. AstraZeneca (Europe) Business Overview

    Table 69. AstraZeneca (Europe) Influenza Vaccination Product and Services

    Table 70. AstraZeneca (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 71. AstraZeneca (Europe) Influenza Vaccination SWOT Analysis

    Table 72. AstraZeneca (Europe) Recent Developments

    Table 73. BioCryst Pharmaceuticals (U.S.) Company Details

    Table 74. BioCryst Pharmaceuticals (U.S.) Business Overview

    Table 75. BioCryst Pharmaceuticals (U.S.) Influenza Vaccination Product and Services

    Table 76. BioCryst Pharmaceuticals (U.S.) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 77. BioCryst Pharmaceuticals (U.S.) Influenza Vaccination SWOT Analysis

    Table 78. BioCryst Pharmaceuticals (U.S.) Recent Developments

    Table 79. Novartis (Europe) Company Details

    Table 80. Novartis (Europe) Business Overview

    Table 81. Novartis (Europe) Influenza Vaccination Product and Services

    Table 82. Novartis (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 83. Novartis (Europe) Influenza Vaccination SWOT Analysis

    Table 84. Novartis (Europe) Recent Developments

    Table 85. DAIICHI SANKYO COMPANY (Asia Pacific) Company Details

    Table 86. DAIICHI SANKYO COMPANY (Asia Pacific) Business Overview

    Table 87. DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination Product and Services

    Table 88. DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 89. DAIICHI SANKYO COMPANY (Asia Pacific) Influenza Vaccination SWOT Analysis

    Table 90. DAIICHI SANKYO COMPANY (Asia Pacific) Recent Developments

    Table 91. GlaxoSmithKline (Europe) Company Details

    Table 92. GlaxoSmithKline (Europe) Business Overview

    Table 93. GlaxoSmithKline (Europe) Influenza Vaccination Product and Services

    Table 94. GlaxoSmithKline (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 95. GlaxoSmithKline (Europe) Influenza Vaccination SWOT Analysis

    Table 96. GlaxoSmithKline (Europe) Recent Developments

    Table 97. Hualan Biological Engineering (Asia Pacific) Company Details

    Table 98. Hualan Biological Engineering (Asia Pacific) Business Overview

    Table 99. Hualan Biological Engineering (Asia Pacific) Influenza Vaccination Product and Services

    Table 100. Hualan Biological Engineering (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 101. Hualan Biological Engineering (Asia Pacific) Influenza Vaccination SWOT Analysis

    Table 102. Hualan Biological Engineering (Asia Pacific) Recent Developments

    Table 103. Mitsubishi Tanabe Pharma (Asia Pacific) Company Details

    Table 104. Mitsubishi Tanabe Pharma (Asia Pacific) Business Overview

    Table 105. Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination Product and Services

    Table 106. Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 107. Mitsubishi Tanabe Pharma (Asia Pacific) Influenza Vaccination SWOT Analysis

    Table 108. Mitsubishi Tanabe Pharma (Asia Pacific) Recent Developments

    Table 109. F. Hoffmann-La Roche (Europe) Company Details

    Table 110. F. Hoffmann-La Roche (Europe) Business Overview

    Table 111. F. Hoffmann-La Roche (Europe) Influenza Vaccination Product and Services

    Table 112. F. Hoffmann-La Roche (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 113. F. Hoffmann-La Roche (Europe) Influenza Vaccination SWOT Analysis

    Table 114. F. Hoffmann-La Roche (Europe) Recent Developments

    Table 115. Sanofi (Europe) Company Details

    Table 116. Sanofi (Europe) Business Overview

    Table 117. Sanofi (Europe) Influenza Vaccination Product and Services

    Table 118. Sanofi (Europe) Influenza Vaccination Revenue in Influenza Vaccination Business (2017-2022) & (US$ Million)

    Table 119. Sanofi (Europe) Influenza Vaccination SWOT Analysis

    Table 120. Sanofi (Europe) Recent Developments

    Table 121. Influenza Vaccination Market Trends

    Table 122. Influenza Vaccination Market Drivers

    Table 123. Influenza Vaccination Market Challenges

    Table 124. Influenza Vaccination Market Restraints

    Table 125. Research Programs/Design for This Report

    Table 126. Key Data Information from Secondary Sources

    Table 127. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Influenza Vaccination Sales Market Share by Type: 2021 VS 2028

    Figure 2. Egg Based Features

    Figure 3. Cell Culture Features

    Figure 4. Recombinant Features

    Figure 5. Global Influenza Vaccination Sales Market Share by Application: 2021 VS 2028

    Figure 6. Hospitals Case Studies

    Figure 7. Research Organizations Case Studies

    Figure 8. Influenza Vaccination Report Years Considered

    Figure 9. Global Influenza Vaccination Revenue, (US$ Million), 2017 VS 2021 VS 2028

    Figure 10. Global Influenza Vaccination Market Size 2017-2028 (US$ Million)

    Figure 11. Global Influenza Vaccination Market Size Market Share by Region: 2021 VS 2028

    Figure 12. Global Influenza Vaccination Revenue Market Share by Region in 2017 VS 2022

    Figure 13. Global Top 10 Influenza Vaccination Countries Ranking by Market Size (US$ Million) in 2021

    Figure 14. Global Influenza Vaccination Market Share by Players in 2021

    Figure 15. Global Top Influenza Vaccination Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Influenza Vaccination as of 2021)

    Figure 16. The Top 10 and 5 Players Market Share by Influenza Vaccination Revenue in 2021

    Figure 17. North America Influenza Vaccination Revenue Market Share by Company in 2021

    Figure 18. North America Influenza Vaccination Revenue Market Share by Type (2017-2028)

    Figure 19. North America Influenza Vaccination Revenue Market Share by Application (2017-2028)

    Figure 20. North America Influenza Vaccination Revenue Share by Country (2017-2028)

    Figure 21. U.S. Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 22. Canada Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 23. Europe Influenza Vaccination Revenue Market Share by Company in 2021

    Figure 24. Europe Influenza Vaccination Revenue Market Share by Type (2017-2028)

    Figure 25. Europe Influenza Vaccination Revenue Market Share by Application (2017-2028)

    Figure 26. Europe Influenza Vaccination Revenue Share by Country (2017-2028)

    Figure 27. Germany Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 28. France Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 29. U.K. Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 30. Italy Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 31. Russia Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 32. Asia Pacific Influenza Vaccination Revenue Market Share by Company in 2021

    Figure 33. Asia Pacific Influenza Vaccination Revenue Market Share by Type (2017-2028)

    Figure 34. Asia Pacific Influenza Vaccination Revenue Market Share by Application (2017-2028)

    Figure 35. Asia Pacific Influenza Vaccination Revenue Share by Region (2017-2028)

    Figure 36. China Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 37. Japan Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 38. South Korea Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 39. India Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 40. Australia Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 41. Taiwan Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 42. Indonesia Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 43. Thailand Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 44. Malaysia Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 45. Philippines Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 46. Vietnam Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 47. Latin America Influenza Vaccination Revenue Market Share by Company in 2021

    Figure 48. Latin America Influenza Vaccination Revenue Market Share by Type (2017-2028)

    Figure 49. Latin America Influenza Vaccination Revenue Market Share by Application (2017-2028)

    Figure 50. Latin America Influenza Vaccination Revenue Share by Country (2017-2028)

    Figure 51. Mexico Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 52. Brazil Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 53. Argentina Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 54. Middle East and Africa Influenza Vaccination Revenue Market Share by Company in 2021

    Figure 55. Middle East and Africa Influenza Vaccination Revenue Market Share by Type (2017-2028)

    Figure 56. Middle East and Africa Influenza Vaccination Revenue Market Share by Application (2017-2028)

    Figure 57. Middle East and Africa Influenza Vaccination Revenue Share by Country (2017-2028)

    Figure 58. Turkey Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 59. Saudi Arabia Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 60. U.A.E Influenza Vaccination Revenue (2017-2028) & (US$ Million)

    Figure 61. Abbott (U.S.) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 62. AstraZeneca (Europe) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 63. BioCryst Pharmaceuticals (U.S.) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 64. Novartis (Europe) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 65. DAIICHI SANKYO COMPANY (Asia Pacific) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 66. GlaxoSmithKline (Europe) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 67. Hualan Biological Engineering (Asia Pacific) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 68. Mitsubishi Tanabe Pharma (Asia Pacific) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 69. F. Hoffmann-La Roche (Europe) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 70. Sanofi (Europe) Revenue Growth Rate in Influenza Vaccination Business (2017-2022)

    Figure 71. Bottom-up and Top-down Approaches for This Report

    Figure 72. Data Triangulation

    Figure 73. Key Executives Interviewed